Huro Probiotics participates in UK research of COVID-19 medication

Vietnamese company Huro Probiotics will cooperate in the UK research of a COVID-19 medicine

According to information posted on the London Stock Exchange on September 7, Destiny Pharma and SporeGen has entered a cooperation in the research and development (R&D) of products from bacteria, called SPORE-COV, that can stimulate the natural immune system and fight against the SARS-COV-2 virus.

The representative of Destiny Pharma said that the project will have the participation of a Vietnamese enterprise, Huro Probiotics – a member of The PAN Group (HSX: PAN) as material provider and developer of standardised manufacturing technology on an industrial scale.

Destiny Pharma, which specialises in the development of a new generation of anti-infection drugs, and SporeGen, which specialises in the application of microbiological spores from the UK, will play a key role in the COVID-19 room product creation project. The British government has also decided to finance £800,000 ($1 million) out of a total of £1.1 million ($1.4 million) with the desire to soon get a low-cost anti-epidemic product for the people.

SPOR-COV was developed from a Sporegen exclusive formulation based on a naturally isolated non-pathogenic bacterium that is administered nasally as a spray. Unlike vaccines, SPOR-COV focuses on utilising the natural (innate) immune system to enhance protection against the SARS-CoV-2 virus a few days after dosing.

The only Vietnamese company participating in the project, Huro Probiotics, formerly the R&D center of The PAN Group, was established in 2012, specializing in research, development and production of probiotics for the pharmaceutical and food industries. One of the prominent product applications of the group is the first gummy product in Vietnam incorporating probiotic strain HU58.

The UK's experience in cooperation and technology transfer from many years ago can be one of the opportunities to help the PAN Group participate in the SPOR-COV R&D project. The representative of Destiny Pharma said that it will transfer the technology of manufacturing SPOR-COV to Huro Probiotics, who surpassed eight other pharmaceutical manufacturers from the UK and the EU to win the bid.